TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV infected~* Currently on ART consisting of at least 3 antiretroviral drugs for at least 12 months prior to study entry and stable (no change in dose) on treatment for at least 3 months prior to study entry~* CD4 count of 100 cells/mm3 or more within 42 days of study entry~* Viral load of 50,000 copies/ml or less within 42 days of study entry~* Willing to use acceptable forms of contraception~* Participants with a Category C AIDS-defining illness during the 12 months prior to study entry may be eligible as long as their CD4 count is 200 cells/mm3 or more at screening. Participants with Kaposi's sarcoma may also be eligible for this study.~Exclusion Criteria:~* Lymphadenopathy greater than 2.0 cm~* Known allergy or sensitivity to study drug or its formulations~* Current drug or alcohol abuse~* Serious illness or hospitalization that, in the opinion of the site investigator, may interfere with the study results~* Prior use of any interleukins~* Systemic cancer chemotherapy, systemic investigational agents, or immunomodulators (e.g., growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interferons) within 90 days prior to study entry~* Heparin within 96 hours prior to study entry, or anticipating the need for heparin within 96 hours after the study injection~* History of cancer (except basal carcinoma of the skin or Kaposi's sarcoma)~* Enlargement of spleen~* History of hypercoagulability (deep vein thrombosis or pulmonary embolism)~* History of seizure disorder~* History of extensive psoriasis, Crohn's disease, uveitis, or other autoimmune disease having induced severe complications~* Significant psychiatric, cardiac, pulmonary, thyroid, renal, or neurological disease requiring therapy~* Positive hepatitis B surface antigen or positive hepatitis C antibody at screening~* Plan to start new ART within 8 weeks after study entry~* Breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmation of renal cell carcinoma with a clear cell histologic component~2. Patients must present with stage IV disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent.~3. Measurable disease according to RECIST criteria are required but patients with evaluable lesions without measurable lesions are allowed to be enrolled to this study~4. ECOG performance status 2 or better~5. Age 18 years or older~6. Adequate bone marrow, hepatic, and renal function~7. Life expectancy of \> 3 months~8. Singed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment~Exclusion Criteria:~1. Known spinal cord compression or carcinomatous meningitis~2. Diagnosis of any serious secondary malignancy within the last 2 years, except for adequately treated basal cell or squamous cell carcinoma of skin, or in situ carcinoma of cervix uteri~3. Hypertension that cannot be controlled by medications (blood pressure \> 150/90 mmHg despite optimal medical therapy)~4. Treatment with anticonvulsant agents and treatment with therapeutic doses of coumadin currently or within 2 weeks prior to first day of sunitinib administration. Low dose coumadin for DVT prophylaxis is permitted (up to 2 mg/day).~5. Pregnancy or breast feeding.~6. Other severe acute or chronic medical or psychiatric condition~7. Prior treatment on sunitinib, sorafenib, or bevacizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sunitinib 4/2 (Type: ACTIVE_COMPARATOR): Sunitinib 50 mg PO 4-week on and 2-week off
- Sunitinib 2/1 (Type: EXPERIMENTAL): Sunitinib 50 mg PO 2-week on 1-week off

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have had a diagnosis of type 2 diabetes mellitus~* Participants who have been treated with insulin therapy (basal insulin, premixed insulin, or basal/mealtime insulin regimen) with or without 1 or 2 oral antidiabetics (OADs) at stable dose for at least 3 months before screening~* Participants who have an HbA1c value ≥7.0% and ≤10.5% at screening if the participant is washing out OADs (dipeptidyl peptidase-4 \[DPP-4\] inhibitors, sulfonylurea \[SU\], or glinides) or ≥7.5% and ≤10.5% at screening if the participant is not washing out OADs~* Participants who have stable weight (±5%) ≥3 months prior to screening~* Participants who have a body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m\^2)~Exclusion Criteria:~* Participants who have a diagnosis of type 1 diabetes~* Participants who have previously received therapy with a glucagon-like peptide-1 receptor agonist within 3 months prior to screening~* Participants who have been previously treated with dulaglutide prior to screening~* Participants who have been treated with 2 of the following at screening: DPP-4 inhibitor, SU, and glinide (ie, DPP-4 inhibitor and SU, or DPP-4 inhibitor and glinide)~* Participants who have been treated with continuous subcutaneous insulin infusion (CSII) at screening~* Participants who have clinically significant gastric emptying abnormality, hepatitis, pancreatitis, renal dysfunction, or thyroid abnormalities~* Participants who have a history of clinically significant cardiovascular disease, transplanted organ, or active or untreated malignancy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dulaglutide (Type: EXPERIMENTAL): Dulaglutide 0.75 milligram (mg) administered once weekly for 16 weeks. After 16-weeks, dulaglutide administered once weekly for 36 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered once weekly for 16 weeks. After 16-weeks, dulaglutide 0.75 mg administered once weekly for 36 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Advisa MRI Clinical Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have a Class I or II indication for implantation of a dual chamber pacemaker according to the American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rhythm Society (HRS) guidelines~* Subjects who are able to undergo a pectoral implant~* Subjects who are able and willing to undergo elective magnetic resonance (MR) scanning without sedation~* Subjects who are geographically stable and available for follow-up at the study center for the length of the study~Exclusion Criteria:~* Subjects with a mechanical tricuspid heart valve~* Subjects with a history of significant tricuspid valvular disease~* Subjects for whom a single dose of 1.0 milligram (mg) dexamethasone acetate may be contraindicated~* Subjects who require a legally authorized representative to obtain consent~* Subjects who have a previously implanted pacemaker or implantable cardioverter defibrillator (ICD) (abandoned pacemaker and/or defibrillator leads are not permitted; however subjects with complete system explants are not excluded)~* Subjects who are immediate candidates for an ICD~* Subjects who require an indicated MR scan, other than those specifically described in the study, before the 4 months follow-up~* Subjects with previously implanted active medical devices~* Subjects with a non-MRI compatible device (such as ICDs or neurostimulators) or material implant (e.g. non-MRI compatible sternal wires, neurostimulators, biostimulators, metals or alloys)~* Subjects with medical conditions that preclude the testing required by the protocol or limit study participation~* Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during this clinical study~* Pregnant women, or women of child bearing potential and who are not on a reliable form of birth control~* Subjects with exclusion criteria required by local law (e.g. age, breastfeeding)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI group (Type: EXPERIMENTAL): Subjects randomized to the MRI group will undergo a one-hour MRI scan, including 16 individual sequences in the chest and head region, at 9-12 weeks post-implant.
- Control group (Type: ACTIVE_COMPARATOR): Subjects randomized to the Control group will wait for one hour without having any MRI scan at 9-12 weeks post-implant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Three types of subject:~Neonates whose mothers are positive for both HBsAg and HBeAg~Neonates whose mothers are positive for only HBsAg~Neonates whose mothers are negative for both HBsAg and HBeAg~INCLUSION CRITERIA:~* Full-term neonates with gestational age from 37 weeks to 42 weeks;~* Apgar scores are no less than 7 at birth;~* Neonates with standard body temperature (auxiliary temperature \< 37.1°);~* Neonates weighing ≥ 2,500 grams at birth;~* Neonates with icteric index within the normal range (physiologic jaundice is permitted);~* Informed consent form signed by parent/guardian;~* The requirements of the clinical trial protocol can be observed on the basis of the opinion of the investigator.~EXCLUSION CRITERIA:~* Subject's parent has a history of family diseases such as convulsion and brain diseases;~* Mothers have low immunologic function or a history of organ transplantation or hemodialysis;~* Subject's parent is allergic to any composition of Hepatitis B vaccine;~* A family history of thrombocytopenia, or other disturbance of blood coagulation, which may result in a contraindication for intramuscular injection;~* Known immunologic function damage;~* Mothers had received gamma globulin or immunoglobulin injection during pregnancy;~* Any congenital malformation~* Known or suspected to suffer from diseases such as active infection and cardiovascular disease;~* Any condition believed by the investigator to have possible impact on trial evaluation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Day
- Healthy Volunteers: t

Study Arms:
- HepavaxGene Stratum 1a (Type: EXPERIMENTAL): Subjects of mothers with chronic hepatitis B (positive for both HBsAg and hepatitis B envelope antigen - HBeAg)
- Comparator vaccine Stratum 1a (Type: ACTIVE_COMPARATOR): Subjects of mothers with chronic hepatitis B (positive for both HBsAg and HBeAg)
- HepavaxGene Stratum 1b (Type: EXPERIMENTAL): Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
- Comparator vaccine Stratum 1b (Type: ACTIVE_COMPARATOR): Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
- HepavaxGene Stratum 2 (Type: EXPERIMENTAL): Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
- Comparator vaccine Stratum 2 (Type: ACTIVE_COMPARATOR): Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of schizophrenia, schizoaffective disorder (depressed type), or schizophreniform disorder~* First major episode of psychotic symptoms occurred within 2 years prior to study entry~* Participant in the UCLA Center for Neurocognition and Emotion in Schizophrenia~Exclusion Criteria:~* Neurological disorder or injury (e.g., encephalitis, epilepsy, traumatic brain injury)~* Mental retardation (e.g., premorbid IQ less than 70)~* Significant alcohol or substance abuse within 6 months prior to study entry~* Inability to complete research measures in English~* Any condition that may make risperidone use medically inadvisable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Long-acting injectible risperidone (Type: EXPERIMENTAL): Participants who are randomly assigned to this arm will be administered the long-acting injectible form of risperidone (Risperdal Consta) every two weeks, plus group skills training and case management, for 12 months.
- Oral risperidone (Type: ACTIVE_COMPARATOR): Participants who are randomly assigned to this arm will be treated with the oral version of risperidone (Risperdal) daily, plus group skills training and case management, for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DE-117 Spectrum 5 Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Primary Open-Angle Glaucoma or Ocular Hypertension in one or both eyes.~* Provide signed written informed consent.~* Diagnosis of POAG or OHT in both eyes.~* Qualifying corrected visual acuity in each eye.~* Qualifying central corneal thickness in each eye.~* Qualifying Day 1 IOP measurement at 3 time-points in both eyes after latanoprost Run-in Period.~* Qualifying Anterior chamber angle.~* Qualifying IOP measurement at 3 time-points during latanoprost Run-in Period.~Exclusion Criteria:~* Patients who cannot safely discontinue use of Ocular Hypotensive Medications during Washout.~* Patients with prior exposure to DE-117.~* History of ocular surgery specifically intended to lower IOP~* Advanced glaucoma in either eye.~* Any corneal abnormality or other condition interfering with or preventing reliable Goldmann applanation tonometry.~* Any ocular surgery or ocular laser treatment within 180 days prior to Visit 1 (Screening) and throughout the study in either eye.~* Females who are pregnant, nursing, or planning a pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DE-117 Ophthalmic Solution 0.002% (Type: EXPERIMENTAL): Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Conversion Study From Cyclosporine to FK506MR Based Immunosuppression in Kidney Transplant Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Serum creatinine \< 200 µmol/l (\< 2.3 mg/dl) at enrollment.~* Female subject of childbearing potential must have a negative serum pregnancy test at enrollment and must agree to maintain effective birth control during the study.~* Capable of understanding the purpose and risks of the study, has been fully informed and has given written informed consent (signed Informed Consent has been obtained).~Exclusion Criteria:~* Previously received an organ transplant other than a kidney.~* Acute rejection episode within 12 weeks prior to enrollment, or an acute rejection episode within the 24 weeks prior to enrollment that required anti-lymphocyte antibody therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Severe hemophilia B defined as ≤ 2 IU/dl (≤ 2%) endogenous FIX~* Male \< 12 years and weight ≥ 13 kg~* History of at least 50 documented prior exposure days to FIX~* No history of, or currently detectable, inhibitor~Key Exclusion Criteria:~* Other coagulation disorders in addition to Hemophilia B~* History of anaphylaxis associated with any FIX or IV immunoglobulin administration~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- rFIXFc Prophylaxis (Type: EXPERIMENTAL): At Baseline and at Day 1, participants receive a single intravenous (IV) injection of prestudy FIX and rFIXFc, respectively, over 10 (±5) minutes at a dose of 50 IU/kg. Immediately after the last PK sampling, the first prophylactic dose of approximately 50 to 60 IU/kg will be administered in clinic as an IV injection.~Dose could be increased or decreased in increments of 10 IU/kg; increases to a maximum of 100 IU/kg and frequency of administration to a maximum of twice weekly, were allowed as indicated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Early Capsule Deployment to Current Standard of Care for Management of Gastrointestinal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years old~* New onset of melena or hematochezia~* Able to sign consent~* Hemodynamically stable (i.e. blood pressure \>100/60 or pulse \<110 at the time of consent)~* ED must plan to admit patient to the hospital or Clinical Decision Unit.~Exclusion Criteria:~* Adults unable to consent~* Individuals who are not yet adults (infants, children, teenagers)~* Pregnant women~* Prisoners~* Prior history of gastroparesis~* Prior history of gastric, or small bowel surgery~* Prior history of Crohn's disease~* Concern for infectious colitis~* Non-English speaking~* Evidence of dysphagia at the time of presentation~* Presence of bright red blood per rectum concerning for hemorrhoids~* Allergy to metoclopramide or erythromycin~* Code status of Do Not Resuscitate/Do Not Intubate (DNR/DNI) or Comfort Measures Only (CMO)~* Prior history of abdominal radiation~* Presence of Implantable Cardioverter Defibrillator (ICD) or pacemaker or other implanted electronic devices~* Abdominal pain suggesting an acute abdomen or obstruction. In clinical practice, only patients with crampy abdominal pain due to Crohn's disease, previous intestinal surgery and a previous history of radiation therapy require a patency capsule or CT enterography before capsule endoscopy.~* Patients who cannot undergo surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early Video Capsule Endoscopy (Type: EXPERIMENTAL): The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the emergency department. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
- Standard of Care Workup Group (Type: NO_INTERVENTION): In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete